Serum prolactin level in male type 2 diabetes mellitus patients at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2024.

Arega Zenaw, Elias Chane, Getnet Fetene, Sintayehu Admas, Nigusie Alemu, Mitkie Tigabie, Belete Biadgo, Abebaw Worede

Abstract read

In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arega ZenawDepartment of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia. azenaw1990@gmail.com.

Elias ChaneDepartment of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia.

Getnet FeteneDepartment of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia.

Sintayehu AdmasDepartment of Hematology and Immunohematology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Nigusie AlemuDepartment of Hematology and Immunohematology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Mitkie TigabieDepartment of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia.

Belete BiadgoDepartment of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia.

Abebaw WoredeDepartment of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anterior pituitary gland secretes the peptide hormone prolactin, which is important for lactation, reproductive health, and metabolic regulation. Its secretion is primarily regulated by dopamine and also its elevated level is known as hyperprolactinemia. The aim of this study was to assess serum prolactin level in T2DM patients at the University of Gondar comprehensive specialized hospital. A comparative cross-sectional study was conducted from June 27 to August 20, 2024 involving 330 study participants selected using systematic random sampling. Of these, 165 were male patients with T2DM and 165 were apparently healthy controls. Sociodemographic, behavioral, and clinical data were measured by structured questionnaires. Hormonal parameters, Fasting blood sugar and lipid profiles were measured by chemiluminescent immunoassay and spectrophotometric principles respectively. Data were analyzed using SPSS version 25. Descriptive statistics, independent t-tests, and binary logistic regression were performed with significance set at p < 0.05. The prevalence of hyperprolactinemia was 9.1% in T2DM patients and 6.1% in the control group. A statistically significant difference in mean serum prolactin level was observed between T2DM and control group (7.79 ± 2.9 vs. 6.81 ± 3.1, p-value = 0.004) respectively. Hyperprolactinemia was more likely to occur in study individuals with high dietary diversity (AOR = 3.213, 95% CI: 1.253-8.239, P-value = 0.015). The incidence of hyperprolactinemia increases by 1.009 (95% CI: 1.001-1.018; P-value = 0.035) for every unit rise in FBS (1 mg/dl). In conclusion, the mean serum prolactin level was significantly higher among T2DM patients compared to healthy control groups. In addition, the prevalence of hyperprolactinemia was higher in T2DM patients than the control groups. Dietary diversity and elevated FBS were a significant predictors of hyperprolactinemia. So, the healthcare providers should consider routine screening of serum prolactin level in patients diagnosed with T2DM.

Indexed as

Diabetes Mellitus, Type 2HyperprolactinemiaProlactinAdultCase-Control StudiesCross-Sectional StudiesEthiopiaHumansMaleMiddle AgedPrevalenceProlactinHyperprolactinemiaNorthwest ethiopiaProlactinT2DM

Identifiers

PMID41387537

DOI10.1038/s41598-025-32477-x

PMCPMC12820058

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.